Secondary Logo

Institutional members access full text with Ovid®

Cyclin-dependent kinase 4/6 inhibitors

what have we learnt across studies, therapy situations and substances

Banys-Paluchowski, Malgorzataa; Krawczyk, Nataliab; Paluchowski, Peterc

Current Opinion in Obstetrics and Gynecology: February 2019 - Volume 31 - Issue 1 - p 56–66
doi: 10.1097/GCO.0000000000000511
BREAST CANCER: Edited by Peter A. Fasching
Buy
SDC

Purpose of review Cyclin-dependent kinases (CDK) are key regulatory enzymes that control cell cycle and cell division. In the recent years, new therapeutic options selectively targeting CDK 4 and 6 have shown promising clinical activity in several solid tumors. Since 2015, three CDK 4/6 inhibitors have been approved for treatment of hormone receptor-positive HER2-negative metastatic breast cancer: palbociclib, ribociclib and abemaciclib. These drugs share a common mechanism of action and have been evaluated in studies with a similar design. The following review gives a clinical overview of the CDK 4/6 inhibitors in breast cancer therapy and highlight current study data with regard to their antitumor efficacy and toxicities.

Recent findings In clinical trials in the first-line and later-line setting, palbociclib, ribociclib and abemaciclib in combination with endocrine therapy significantly prolonged progression-free survival. The most common adverse events during treatment with CDK 4/6 inhibitors are neutropenia, fatigue and gastrointestinal symptoms.

Summary CDK 4/6 inhibitors represent a valuable treatment option for patients with metastatic hormone receptor-positive HER2-negative breast cancer. Although the clinical efficacy of the three agents seems similar, their toxicity profiles differ. Therefore, the choice of a CKD 4/6 inhibitor depends on patient's characteristics and individual preferences.

Video abstract In the video, the author describes the content of the review and present the main topics discussed in the article (http://links.lww.com/COOG/A44).

aDepartment of Gynecology and Obstetrics, Asklepios Klinik Barmbek, Hamburg

bDepartment of Obstetrics and Gynecology, Heinrich-Heine-University Düsseldorf, Düsseldorf

cDepartment of Gynecology and Obstetrics, Regio Klinikum Pinneberg, Pinneberg, Germany

Correspondence to Malgorzata Banys-Paluchowski, Department of Gynecology and Obstetrics, Asklepios Klinik Barmbek, Rübenkamp 220, 22307 Hamburg, Germany. E-mail: banys.malgorzata@yahoo.com

Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Website (www.co-obgyn.com).

Copyright © 2019 YEAR Wolters Kluwer Health, Inc. All rights reserved.